We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+2.04%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$16.2B
AUM Growth
-$1.27B
(-7.2%)
Cap. Flow
-$1.42B
Cap. Flow
% of AUM
-8.75%
Top 10 Holdings %
Top 10 Hldgs %
18.5%
Holding
1,414
New
206
Increased
348
Reduced
372
Closed
450
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$456M |
| 2 |
Intel
INTC
|
+$290M |
| 3 |
Union Pacific
UNP
|
+$159M |
| 4 |
AT&T
T
|
+$143M |
| 5 |
Philip Morris
PM
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$394M |
| 2 |
AstraZeneca
AZN
|
+$307M |
| 3 |
Gilead Sciences
GILD
|
+$212M |
| 4 |
TSMC
TSM
|
+$187M |
| 5 |
Canadian National Railway
CNI
|
+$177M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.82% |
| 2 | Financials | 15.5% |
| 3 | Healthcare | 9.75% |
| 4 | Industrials | 8.83% |
| 5 | Consumer Discretionary | 8.82% |
Similar funds
VGA
Arrowstreet Capital's Q1 2015 Portfolio in Review
As of Q1 2015, Arrowstreet Capital held 1,414 positions worth $16.2B, down 7.2% from $17.5B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Arrowstreet Capital withdrew a net $1.42B in Q1 2015, closing 450 positions and reducing 372 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $394M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 21% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Arrowstreet Capital opened a new position in Apple worth $470M.
- Arrowstreet Capital's largest Q1 2015 buy was Apple: 15,110,160 shares worth $470M.
- Arrowstreet Capital added most to Intel in Q1 2015, an estimated $290M increase.
- Arrowstreet Capital's biggest Q1 2015 reduction was AstraZeneca, cutting an estimated $307M.
- Arrowstreet Capital fully exited Teva Pharmaceuticals in Q1 2015, selling an estimated $394M.
- Arrowstreet Capital's ten largest holdings make up 18% of its $16.2B portfolio in Q1 2015.
- Arrowstreet Capital opened 206 new positions and closed 450 in Q1 2015.
- Arrowstreet Capital's portfolio value fell 7.2% quarter-over-quarter to $16.2B.
Based on Arrowstreet Capital's 13F filing for Q1 2015, filed 15 May 2015.